SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Hasselgren Mikael)
 

Search: WFRF:(Hasselgren Mikael) > Pharmacological tre...

Pharmacological treatment of asthma in Sweden from 2005 to 2015

Ahlroth Pind, Caroline (author)
Uppsala universitet,Lung- allergi- och sömnforskning
Ställberg, Björn (author)
Uppsala universitet,Allmänmedicin och preventivmedicin
Lisspers, Karin (author)
Uppsala universitet,Allmänmedicin och preventivmedicin
show more...
Sundh, Josefin, 1972- (author)
Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Department of Respiratory Medicine
Kisiel, Marta A. (author)
Uppsala universitet,Arbets- och miljömedicin
Sandelowsky, Hanna (author)
NVS, Section for Family Medicine and Primary Care, Karolinska Institutet, Stockholm, Sweden; Academic Primary Care Centre, Region Stockholm, Sweden; Department of Medicine, Clinical Epidemiology Division, Karolinska Institute, Stockholm, Sweden
Nager, Anna (author)
NVS, Section for Family Medicine and Primary Care, Karolinska Institutet, Stockholm, Sweden
Hasselgren, Mikael, 1964- (author)
Örebro universitet,Institutionen för medicinska vetenskaper,Centre for Clinical Research and Education, Karlstad, Sweden
Montgomery, Scott (author)
Department of Medicine, Clinical Epidemiology Division, Karolinska Institute, Stockholm, Sweden; Clinical Epidemiology and Biostatistics, School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; Department of Epidemiology and Public Health, University College London, London, UK
Janson, Christer (author)
Uppsala universitet,Lung- allergi- och sömnforskning
show less...
 (creator_code:org_t)
Marcel Dekker, 2024
2024
English.
In: Journal of Asthma. - : Marcel Dekker. - 0277-0903 .- 1532-4303. ; 61:4, s. 313-321
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • OBJECTIVE: Despite access to effective therapies many asthma patients still do not have well-controlled disease. This is possibly related to underuse of inhaled corticosteroids (ICS) and overuse of short-acting β2-agonists (SABA). Our aim was to investigate longitudinal trends and associated factors in asthma treatment.METHODS: Two separate cohorts of adults with physician-diagnosed asthma were randomly selected from 14 hospitals and 56 primary health centers in Sweden in 2005 (n = 1182) and 2015 (n = 1225). Information about symptoms, maintenance treatment, and use of rescue medication was collected by questionnaires. Associations between treatment and sex, age, smoking, education, body mass index (BMI), physical activity, allergic asthma, and symptom control were analyzed using Pearson's chi2-test. Odds ratios (ORs) were calculated using logistic regression.RESULTS: Maintenance treatment with ICS together with long-acting β2-agonists (LABA) and/or montelukast increased from 39.2% to 44.2% (p = 0.012). The use of ICS + LABA as-needed increased (11.1-18.9%, p < 0.001), while SABA use decreased (46.4- 41.8%, p = 0.023). Regular treatment with ICS did not change notably (54.2-57.2%, p = 0.14). Older age, former smoking, and poor symptom control were related to treatment with ICS + LABA/montelukast. In 2015, 22.7% reported daily use of SABA. A higher step of maintenance treatment, older age, obesity, shorter education, current smoking, allergic asthma, low or very high physical activity, and a history of exacerbations were associated with daily SABA use.CONCLUSIONS: The use of ICS + LABA both for maintenance treatment and symptom relief has increased over time. Despite this, the problem of low use of ICS and high use of SABA remains.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Lungmedicin och allergi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Respiratory Medicine and Allergy (hsv//eng)

Keyword

LABA
Longitudinal study
SABA
inhaled corticosteroids
long-acting β2-agonists
short-acting β2-agonists

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view